VMT01/02 (Combination with Nivolumab)
Melanoma (MC1R+)
Phase 1/2Enrolling (3.0 mCi)
Key Facts
About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage biotech on a mission to transform cancer treatment with its innovative targeted alpha-particle therapy (TAT) platform. Formed in 2023 via a strategic merger, the company leverages a proprietary Pb-212-based approach to deliver high-energy, short-range radiation directly to cancer cells, minimizing damage to healthy tissue. Its strategy focuses on advancing a pipeline of image-guided theranostics for neuroendocrine tumors, melanoma, and other solid tumors, positioning it at the forefront of the next wave in radiopharmaceuticals.
View full company profileTherapeutic Areas
Other Melanoma (MC1R+) Drugs
| Drug | Company | Phase |
|---|---|---|
| VMT01/02 (Monotherapy) | Perspective Therapeutics | Phase 1/2 |